# Protein Manipulation via Dielectrophoresis: Theoretical Principles and Emerging Microfluidic Platforms

**Authors:** Zuriel Da En Shee, Ervina Efzan Mhd Noor, Mirza Farrukh Baig

PMC · DOI: 10.3390/mi16050531 · Micromachines · 2025-04-29

## TL;DR

This review explores the use of dielectrophoresis for protein manipulation in microfluidic systems, highlighting challenges and theoretical considerations.

## Contribution

The paper provides a comprehensive review of DEP principles and challenges specific to protein manipulation at micro- to nano-scales.

## Key findings

- Protein manipulation via DEP is hindered by their small size, complex morphology, and sensitivity to environmental factors.
- Microfluidic platforms must account for electrohydrodynamic effects, electrolysis, and joule heating in protein DEP studies.
- A critical review of protein bioparticles investigated using DEP is presented, along with medium and platform considerations.

## Abstract

Dielectrophoresis (DEP) has been widely employed in microfluidic platforms for particle or cell manipulation in biomedical science applications due to its accurate, fast, label-free, and low-cost diagnostic technique. However, the application of the DEP technique towards protein manipulation has yet to be extensively explored due to the challenges of the complexity of protein itself, such as its complex morphologies, extremely minuscule particle size, inherent electrical properties, and temperature sensitivity, which make it relatively more challenging. Furthermore, given that protein DEP investigation requires entering the micro- to nano-scale level of DEP configuration, various challenging factors such as electrohydrodynamic effects, electrolysis, joule heating, and electrothermal force that emerge will make it more difficult in realizing protein DEP investigation. This review study has discussed the fundamental theory of DEP and considerations toward protein DEP manipulation. In particular, it focused on the DEP theoretical principle towards protein, protein DEP application challenges, microfluidic platform considerations, medium considerations, and a critically reviewed list of protein bioparticles that have been investigated were all highlighted.

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, MSMB (microseminoprotein beta) [NCBI Gene 4477] {aka HPC13, IGBF, MSP, MSPB, PN44, PRPS}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, ANXA3 (annexin A3) [NCBI Gene 306] {aka ANX3}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, EN2 (engrailed homeobox 2) [NCBI Gene 2020], FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, KLK2 (kallikrein related peptidase 2) [NCBI Gene 3817] {aka KLK2A2, hGK-1, hK2}, SAA [NCBI Gene 6287], ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** PTB (MESH:D047928), breast cancer (MESH:D001943), cancer (MESH:D009369), injury to (MESH:D014947), prostate cancer (MESH:D011471), AC (MESH:C536589)
- **Chemicals:** amino acids (MESH:D000596), graphene (MESH:D006108), Britton-Robinson buffer (-), F108 (MESH:C000613702), SiO2 (MESH:D012822), Pluronic  F108 (MESH:D020442), HEPES (MESH:D006531), hafnium oxide (MESH:C545179), KCL (MESH:D011189), PBS (MESH:D007854), polydimethylsiloxane (MESH:C013830), sulfonic acid (MESH:D013451), EDTA (MESH:D004492), PEGDA (MESH:C437167), gold (MESH:D006046), acid (MESH:D000143), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (MESH:C410687), salt (MESH:D012492), oxygen (MESH:D010100), water (MESH:D014867), CHAPS (MESH:C028213)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** V470 V
- **Cell lines:** MCF7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12114388/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12114388/full.md

## References

111 references — full list in the complete paper: https://tomesphere.com/paper/PMC12114388/full.md

---
Source: https://tomesphere.com/paper/PMC12114388